Public Funding for E-Breathe LTD.

"E-breather: Electronic inhalation device for drug delivery that improves effectiveness of delivery and patient compliance for respiratory conditions. The development of an inhalation device aims to reduce healthcare costs and enhance patient outcomes via a combination of: 1. Enhancing real-world effectiveness of drug delivery to the patient: The device senses airflow and only releases the drug into the airstream when the inhalation parameters are suitable to optimise drug absorption thereby maximising the actual delivery of the drug during use. The device provides easy-to-understand real-time feedback to the patient on every use, indicating successful or unsuccessful drug administration. Thereby providing a continuous source of training in correct usage. 2\. Providing information and analytical tools to the healthcare provider to better manage individual patients. The device intelligently collects patient data on how effectively they used the device and how frequently through the day. This can be used by clinicians and carers in personalising therapy, addressing non-adherence and understanding the outcomes of the medicine with individual patients. Addressing the quality, adherence and outcomes can then lead to reduced A&E attendance, better self-management and improved health for the patient. Furthermore, it creates a data set (which is not available today) which could introduce machine learning to adapt and personalise care for patients. Initially this will focus on the specific condition data but can be extended to the patient's comorbidity data and environmental data (eg air pollution level) which have an impact on exacerbations of the condition across patient groups. 3\. Providing a large source of data to generate linkages between environmental factors (e.g. air quality data) and optimal preventative drug levels to manage chronic respiratory diseases."